Biomarkers in breast cancer

Abstract

Treatment decision making in breast cancer is based on several clinicopathological factors such as patient age, menopausal status, tumor grade, tumor size, lymph node status and also biomarkers, particularly ER, PgR and HER2 overexpression. New biomarkers measured as monitoring, prognostic, and predictive factors have been investigated. The development of high technologies in genomics has led to a new molecular reclassification of breast cancer and to better understanding of essential biology. Recently, two major clinical studies have begun aiming at validating two important new multigene prognostication tools for breast cancer: the TAILORx trial with Oncofype DX™, and the MINDACT trial with MammaPrint®.